TAILORED-TREATMENT
DEVELOPMENT OF TAILORED ANTIMICROBIAL TREATMENT REGIMENS AND NOVEL HOST- PATHOGEN INSIGHTS FOR RESPIRATORY TRACT INFECTIONS AND SEPSIS
| Coordinatore | ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Organization address
address: 's Gravendijkwal 230 contact info |
| Nazionalità Coordinatore | Netherlands [NL] |
| Totale costo | 7˙767˙671 € |
| EC contributo | 5˙975˙383 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2013-INNOVATION-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-08-01 - 2017-07-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Organization address
address: 's Gravendijkwal 230 contact info |
NL (ROTTERDAM) | coordinator | 1˙438˙430.00 |
| 2 |
MEMED DIAGNOSTICS LTD
Organization address
address: NAHUM HETH STREET 5 contact info |
IL (TIRAT CARMEL) | participant | 1˙512˙452.80 |
| 3 |
GOETEBORGS UNIVERSITET
Organization address
address: VASAPARKEN contact info |
SE (GOETEBORG) | participant | 1˙012˙720.00 |
| 4 |
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Organization address
address: HEIDELBERGLAAN 100 contact info |
NL (UTRECHT) | participant | 729˙987.00 |
| 5 |
NORAY BIOINFORMATICS SL
Organization address
address: PARQUE TECNOLOGICO 801A contact info |
ES (DERIO) | participant | 528˙411.80 |
| 6 |
HADASSAH MEDICAL ORGANIZATION
Organization address
address: n/a contact info |
IL (JERUSALEM) | participant | 496˙381.40 |
| 7 |
IBEXPERTS Ltd.
Organization address
address: HAALON STREET 16A contact info |
IL (RAANANA) | participant | 257˙000.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Though of tremendous benefit, the overuse of antibiotics has lead to the emergence of antibiotic resistance and may cause adverse events that impact on patient healthcare. Current diagnostic tools for facilitating the appropriate use of antibiotics in patients are inadequate.
We will establish a broad-based strategy (not limited to a particular antibiotic group) that can be implemented on a broad scale to increase the effectiveness of antimicrobial therapy, reduce adverse events, and help limit the emergence of antimicrobial resistance in children and adults.
At the heart of the TAILORED-Treatment project is a prospective clinical study in which we will recruit 1200 patients (>2000 patient samples) presenting with respiratory tract infections and/or sepsis. Patient cohorts will include equal representation of genders, children and adults. State-of-the-art molecular technologies will be applied to characterize host-pathogen interactions at the genomic, transcriptomic, proteomic and clinical level, resulting in a large-scale and unique multi-dimensional dataset. The consortium partners will develop new computational tools to interrogate this data, in order to provide new insights into personalized host-pathogen interactions, including the discovery of novel biomarkers for physicians to use in patient diagnosis and disease monitoring.
Concurrently, using this data, we will construct a predictive personalized treatment algorithm that will lead to informed and personalized antimicrobial treatment regimens (indication, dosage, and duration) that are tailored to the needs (type of infection, presence of novel biomarkers etc) of children and adults presenting with respiratory infections and sepsis.
This unique multi-dimensional dataset and personalized predictive treatment algorithm will be built into an easily navigable web-based, free-to-use, decision support system for use by physicians to explore and assist in patient-tailored antimicrobial treatment decisions.'